Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study - Concepedia

Concepedia

Publication | Open Access

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

DOI Full Paper Access

32

Citations

12

References

2020

Year

Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Todd M. Bauer, Ana M. Molina, Ralph J. Hauke, James A. Reeves, Sunil Babu, Peter J. Van Veldhuizen, Bradley G. Somer,

Clinical Genitourinary Cancer

Abstract

This study validates the safety and efficacy of nivolumab 240 mg Q2W flat-dose monotherapy for previously treated advanced ccRCC and adds to previous safety and efficacy data using the 3 mg/kg Q2W dose.

References

	Year	Citations

Page 1